Although the 2-stage surgical approach was the most cost-effective strategy for individuals with MLH1 and MSH6 variants, it was associated with an increased risk of cancer compared with risk-reducing hyst-BSO at age 40 years. The gene discussed is MSH6; the disease is cancer.